CalAmp (Nasdaq: CAMP), an advanced technology solutions company, has signed a strategic collaboration with Cryoport (Nasdaq: CYRX) (Nasdaq: CYRXW), a temperature-controlled logistics company dedicated to the life sciences industry.
It was reported yesterday that the collaboration is aimed at developing a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments. This research and development collaboration is aimed at improving the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.
Along with CalAmp, Cryoport is exploring an advanced supply chain visibility service that will monitor, in real-time, environmental readings for regenerative medicine product shipments using Bluetooth sensor technology. If successful, the combination of the Cryoport Express Shippers and the Cryoportal Logistics Management Platform, coupled with CalAmp's new-to-market SC iOn Tag Bluetooth sensor technology and SC iOn Command platform, is to allow Cryoport to offer another advanced logistics solution that would pro-actively manage supply chain visibility across multi-mode global shipping routes.
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress